Therapeutic effect of anti CEACAM6 monoclonal antibody against lung adenocarcinoma by enhancing anoikis sensitivity.

摘要: Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) plays a crucial role in tumorigenesis of lung cancer. However, the therapeutic potential for anti CEACAM6 monoclonal antibody (mAb) has only been limitedly explored. Here, we evaluate naked mAb against adenocarcinoma. Clone 8F5, recognizing B domain CEACAM6, is established by immunizing A549 cells and screening clones double positive A549 CEACAM6-Fc recombinant protein. We found that 85.7% 70 resected adenocarcinoma tissue sections were whereas all squamous carcinoma examined negative. cells with high levels demonstrated more aggressive growth nature showed increased paclitaxel chemosensitivity upon 8F5 binding. Treatment to decreased cellular expression reversed anoikis resistance. also status Akt phosphorylation apoptosis via caspase activation. In mouse model xenotransplanted A549 cells, treatment alone 40% tumor inhibition. When combined treatment, markedly enhanced inhibition, up 80%. summary, demonstrate an effective whose effect further paclitaxel.